Showing results (1241-1250 of 3,351) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|March 20, 2019
The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology AppraisalEdward Cox, Ros Wade, Mathilde Peron, et al.
Pharmacoeconomics|February 13, 2014
Valuation of EQ-5D-3L health states in Singapore: modeling of time trade-off values for 80 empirically observed health statesNan Luo, Pei Wang, Julian Thumboo, et al.
Pharmacoeconomics|February 12, 2014
Can the real opportunity cost stand up: displaced services, the straw man outside the roomSimon Eckermann, Brita Pekarsky
Pharmacoeconomics|February 7, 2014
Treatment, monitoring, and economic outcomes of venous thromboembolism among hospitalized patients in ChinaEric Q Wu, Jipan Xie, Chun Wu, et al.
Pharmacoeconomics|February 8, 2014
A systematic review of the quality of economic models comparing thrombosis inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary interventionMaximilian H M Hatz, Reiner Leidl, Nichola A Yates, et al.
Pharmacoeconomics|February 8, 2014
Fibromyalgia: disease synopsis, medication cost effectiveness and economic burdenTracy L Skaer
Pharmacoeconomics|January 23, 2017
Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case StudyMatthew Franklin, Sarah Davis, Michelle Horspool, et al.
Pharmacoeconomics|September 6, 2019
Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic ReviewDongzhe Hong, Lei Si, Minghuan Jiang, et al.
Pharmacoeconomics|August 3, 2019
Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's DiseaseHeather Catt, Keith Bodger, Jamie J Kirkham, et al.
Pharmacoeconomics|April 26, 2015
Exploring the Use of Cost-Benefit Analysis to Compare Pharmaceutical Treatments for MenorrhagiaSabina Sanghera, Emma Frew, Janesh Kumar Gupta, et al.
Pageof 336